| Literature DB >> 31801085 |
Xi-He Qin1, Zhou Wu2, Jing-Hua Dong3, Yuan-Ning Zeng3, Wen-Chao Xiong2, Ce Liu3, Meng-Yao Wang3, Min-Zhen Zhu3, Wen-Jun Chen3, Yuan Zhang3, Qi-Yuan Huang3, Xin-Hong Zhu4.
Abstract
Major depression is a serious global health concern; however, the pathophysiology underlying this condition remains unclear. While numerous studies have focused on brain-specific mechanisms, few have evaluated the role of peripheral organs in depression. Here, we show that the liver activates an intrinsic metabolic pathway that can modulate depressive-like behavior. We find that chronic stress specifically increases the protein levels of monomeric and oligomeric soluble epoxide hydrolase (sEH), a key enzyme in epoxyeicosatrienoic acid (EET) signaling, in the liver. Hepatic deletion of Ephx2 (which encodes sEH) results in antidepressant-like effects, while the hepatic overexpression of sEH induces depressive phenotypes. The activity of sEH in hepatocytes modulates the plasma levels of 14,15-EET, which then interacts with astrocytes in the medial prefrontal cortex to mediate the effects of hepatic Ephx2 deletion. These results suggest that targeting mechanisms underlying the hepatic response to stress would increase our therapeutic options for the treatment of depression.Entities:
Keywords: 14,15-EET; 14,15-epoxyeicosatrienoic acid; biomarkers; liver; major depressive disorder; oligomerization; soluble epoxide hydrolase; therapy
Year: 2019 PMID: 31801085 DOI: 10.1016/j.celrep.2019.11.006
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423